SCYNEXIS, Inc.
SCYXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company carries a $339.2M market cap, placing it firmly in the small-cap category. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Market Cap
$339.2M
Beta
1.10
P/E (TTM)
—
P/E (Fwd)
-1.69
EPS (TTM)
$-3.67
EPS (Fwd)
$-2.52
ROE
-53.4%
ROA
-21.0%
Cash
$59.3M
Total Debt
$2.1M
Free CF
$2.4M
52W Change
-26.4%
Annual Financials
Cash vs Debt
With $59.3M in cash and $2.1M in debt, SCYX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $2.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -53.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $5.1M (2022) to $20.6M (2025), reflecting a 305% increase over the period.
With cash comfortably exceeding debt, SCYX has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing SCYX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.